世界科学技术-中医药现代化
世界科學技術-中醫藥現代化
세계과학기술-중의약현대화
WORLD SCIENCE AND TECHNOLOGY-MODERNIZATION OF TRADITIONAL CHINESE MEDICINE
2013年
5期
891-895
,共5页
丹蛭降糖胶囊%早期糖尿病肾病%尿白蛋白排泄率%NF-κB
丹蛭降糖膠囊%早期糖尿病腎病%尿白蛋白排洩率%NF-κB
단질강당효낭%조기당뇨병신병%뇨백단백배설솔%NF-κB
Danzhi Jiangtang Capsule%early diabetic nephropathy%urinary albumin excretion rate%NF-κB
目的：观察丹蛭降糖胶囊对早期糖尿病肾病（EDN）患者外周血单个核细胞中核转录因子（NF-资B）和血清MCP-1，TGF-β1等炎症指标及尿白蛋白排泄率（UAER）的影响，探讨丹蛭降糖胶囊对EDN抗炎作用及肾保护的可能机制。方法：以导入期后符合纳入标准的72例EDN患者为研究对象，随机分为对照组和治疗组。2组均采用以缬沙坦为基础的西医综合治疗方案，治疗组在此基础上加用丹蛭降糖胶囊，2组疗程均为8周。观察治疗前后MCP-1，NF-资B，TGF-β1及UAER的变化。结果：MCP-1，NF-资B及TGF-β1与UAER呈显著正相关（P<0.05或P<0.01），与治疗前比较，对照组与治疗组治疗后MCP-1， NF-资B，TGF-β1及UAER均明显下降（P<0.05），与对照组比较，治疗组治疗后MCP-1，NF-资B，TGF-β1及UAER均明显降低（P<0.05或P<0.01）。结论：丹蛭降糖胶囊可降低尿白蛋白排泄率，延缓肾脏损伤，从而下调患者血MCP-1，NF-资B及TGF-β1的水平，阻断炎症介质的表达，抑制炎症反应，改善EDN微炎症状态，可能是其保护肾脏功能的重要机制之一。
目的：觀察丹蛭降糖膠囊對早期糖尿病腎病（EDN）患者外週血單箇覈細胞中覈轉錄因子（NF-資B）和血清MCP-1，TGF-β1等炎癥指標及尿白蛋白排洩率（UAER）的影響，探討丹蛭降糖膠囊對EDN抗炎作用及腎保護的可能機製。方法：以導入期後符閤納入標準的72例EDN患者為研究對象，隨機分為對照組和治療組。2組均採用以纈沙坦為基礎的西醫綜閤治療方案，治療組在此基礎上加用丹蛭降糖膠囊，2組療程均為8週。觀察治療前後MCP-1，NF-資B，TGF-β1及UAER的變化。結果：MCP-1，NF-資B及TGF-β1與UAER呈顯著正相關（P<0.05或P<0.01），與治療前比較，對照組與治療組治療後MCP-1， NF-資B，TGF-β1及UAER均明顯下降（P<0.05），與對照組比較，治療組治療後MCP-1，NF-資B，TGF-β1及UAER均明顯降低（P<0.05或P<0.01）。結論：丹蛭降糖膠囊可降低尿白蛋白排洩率，延緩腎髒損傷，從而下調患者血MCP-1，NF-資B及TGF-β1的水平，阻斷炎癥介質的錶達，抑製炎癥反應，改善EDN微炎癥狀態，可能是其保護腎髒功能的重要機製之一。
목적：관찰단질강당효낭대조기당뇨병신병（EDN）환자외주혈단개핵세포중핵전록인자（NF-자B）화혈청MCP-1，TGF-β1등염증지표급뇨백단백배설솔（UAER）적영향，탐토단질강당효낭대EDN항염작용급신보호적가능궤제。방법：이도입기후부합납입표준적72례EDN환자위연구대상，수궤분위대조조화치료조。2조균채용이힐사탄위기출적서의종합치료방안，치료조재차기출상가용단질강당효낭，2조료정균위8주。관찰치료전후MCP-1，NF-자B，TGF-β1급UAER적변화。결과：MCP-1，NF-자B급TGF-β1여UAER정현저정상관（P<0.05혹P<0.01），여치료전비교，대조조여치료조치료후MCP-1， NF-자B，TGF-β1급UAER균명현하강（P<0.05），여대조조비교，치료조치료후MCP-1，NF-자B，TGF-β1급UAER균명현강저（P<0.05혹P<0.01）。결론：단질강당효낭가강저뇨백단백배설솔，연완신장손상，종이하조환자혈MCP-1，NF-자B급TGF-β1적수평，조단염증개질적표체，억제염증반응，개선EDN미염증상태，가능시기보호신장공능적중요궤제지일。
This study was aimed to observe the effect of Danzhi Jiangtang Capsule ( DJC ) on NF-κB in the peripheral blood mononuclear cell , and inflammation indices such as serum MCP-1 , TGF-β1 and urinary albu-min excretion rate ( UAER ) in early diabetic nephropathy ( EDN ) , in order to discuss the possible mechanism of DJC on anti-inflammatory and renal protection effect of EDN. A total of 72 EDN patients which met the in-clusion criteria after the start-up stage were taken as research objects . They were randomly divided into the control group and the treatment group. The western comprehensive treatment plan was given to both groups. In the treatment group, DJC was added. And the treatment course was 8 weeks. Changes of MCP-1, NF-κB, TGF-β1 and UAER were observed before and after the treatment . The results showed that MCP-1 , NF-κB and TGF-β1 had significant positive correlation with UAER ( P < 0 . 05 , or P < 0 . 01 ) . Compared to pre-treat- <br> ment , the levels of MCP-1 , NF-κB , TGF-β1 and UAER in the control group and treatment group after treat-ment were significantly declined ( P < 0 . 05 ) . Compared with the control group , after treatment , the levels of MCP-1 , NF-κB , TGF-β1 and UAER of the treatment group were obviously reduced ( P < 0 . 05 , or P <0 . 01 ) . It was concluded that DJC can reduce the UAER , delay the renal injury , and downregulate levels of MCP-1, NF-κB and TGF-β1, block the expression of inflammatory mediators, inhibit inflammatory reaction and improve microinflammatory state of EDN. This may be one of the important mechanisms in the protection of renal function .
